 Online Presentation Release Date: Monday, December 17, 2018 Expiration Date: Tuesday, December 17, 2019 |
EDUCATIONAL OVERVIEW The management of patients with pulmonary arterial hypertension (PAH) has undergone a vast transformation over the past decade with an improved understanding of the disease and an expansion of treatment options. Though patient survival was once considered the main treatment goal of PAH, outcomes can now include improved hemodynamics, prevention of clinical worsening, and improved quality of life. A key challenge in improving outcomes is early identification of the disease and initiating aggressive treatment. Greater emphasis is also being placed in identifying prognostic factors and assessing patient risk in order to tailor therapy accordingly. Treatment options for PAH are complex and dosing regimens must be specifically followed to avoid serious safety consequences. Research in the pathophysiology of PAH has revealed three major pathways involved in the disease process: the endothelin, nitric oxide, and prostacyclin pathways. Over the past two decades, several treatment options have become available that target these pathways that allow clinicians flexibility is designing optimal regimens. The recent availability of subcutaneous and oral medications allows greater ease of dosing and can expand the prescriber base beyond PAH specialists. Furthermore, the use of combination therapy is increasingly becoming standard of care as more and more clinical trial results support the use of this approach. However, treatment must be individualized based on disease severity and patient factors. Clinicians responsible for the management of patients with PAH must have a thorough understanding of PAH medications, including transitioning care between hospital and home, in order to safely and effectively manage the disease.
|
TARGET AUDIENCE This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems, outpatient clinics, managed care organizations, long-term care facilities, and academia. This program will target pharmacists who are responsible for the safe and effective use of medications utilized for the treatment of patients with PAH.
LEARNING OBJECTIVES Upon completing this activity, participants will be able to:
FACULTY
|
|||||||
| | ||||
Pharmacists ACPE UAN: 0473-9999-18-009-H01-P Activity type: Knowleddge-basedFor questions regarding the accreditation of this activity, please contact us at info@jointsponsor.com
Method of Participation and Instruction for Credit
Disclosure of Conflicts of Interest In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer. |
Disclosures Dr. Cuttica does not discuss any off-label uses.
Fee Hardware/Software Requirements Software/Hardware Connection Speed System Check Copyright Statement Privacy Policy Joint Providership Commercial Support This activity is supported by an educational grant from Actelion Pharmaceuticals. |
|||
Center for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hour (0.1 CEU) of continuing pharmacy education credits for participating in this activity.By clicking below, I acknowledge that I have read the entire CE information. |
   |
